Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00359_DB00440_nanopub.RAQb_yQgdWhIeLZqkr6yCEOWkqmeVRWxm5LQsfZGnd3Go#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00359_DB00440 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00359_DB00440 label "DDI between Sulfadiazine and Trimethoprim - The strong CYP2C9 inhibitor, Sulfadiazine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfadiazine is initiated, discontinued or dose changed. [drugbank_resource:DB00359_DB00440]" assertion.
- drugbank_resource:DB00359_DB00440 identifier "drugbank_resource:DB00359_DB00440" assertion.
- drugbank_resource:DB00359_DB00440 title "DDI between Sulfadiazine and Trimethoprim - The strong CYP2C9 inhibitor, Sulfadiazine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfadiazine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00440 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00359_DB00440 assertion.
- drugbank:DB00359 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00359_DB00440 assertion.